Table 2

Disease activity and lipid variables for the patients who followed the diet regimens for at least 3 months


Vegan diet patients
Non-vegan diet patients


Baseline
3 months
P value
12 months
P value
Baseline
3 months
P value
12 months
P value

DAS28a
5.3 (5.0–5.7)
4.7 (4.3–5.2)
0.002
4.3 (3.8–4.9)
<0.001
5.3 (4.9–5.6)
5.0 (4.6–5.3)
0.014
5.0 (4.6–5.4)
0.19
HAQ scorea
1.4 (1.2–1.5)
1.1 (0.9–1.3)
0.010
1.0 (0.8–1.2)
0.001
1.3 (1.1–1.5)
1.2 (1.0–1.4)
0.62
1.2 (1.0–1.4)
0.59
CRPb
13 (6–26)
11 (5–29)
0.68
5 (4–20)
0.008
22 (5–32)
10 (5–33)
0.07
12 (4–19)
0.28
Albumina
36 (34–37)
34 (33–35)
0.013
36 (35–38)
0.43
35 (34–37)
37 (35–39)
0.06
37 (35–38)
0.06
Cholesterolb
5.2 (4.4–5.7)
4.3 (3.9–5.0)
<0.001
4.3 (3.8–5.1)
0.003
4.7 (4.2–5.3)
5.1 (4.3–5.5)
0.20
5.0 (4.0–5.5)
0.68
Triglyceridesa
1.1 (1.0–1.3)
1.2 (1.0–1.3)
0.43
1.1 (0.9–1.2)
0.32
1.1 (0.9–1.5)
1.2 (0.7–1.6)
0.79
1.1 (0.8–1.3)
0.69
HDLa
1.4 (1.3–1.5)
1.3 (1.2–1.4)
0.14
1.4 (1.3–1.6)
0.22
1.3 (1.2–1.3)
1.3 (1.2–1.4)
0.045
1.3 (1.2–1.4)
0.07
LDLb
3.2 (2.6–3.7)
1.3 (1.2–1.6)
<0.001
2.4 (2.1–3.0)
<0.001
2.9 (2.5–3.4)
3.1 (1.2–1.5)
0.23
3.2 (2.4–3.5)
0.83
LDL/HDLa
2.7 (2.2–3.1)
2.0 (1.8–2.3)
<0.001
1.9 (1.6–2.2)
<0.001
2.4 (2.2–2.7)
2.5 (2.2–2.7)
1.00
2.2 (2.0–2.5)
0.22
oxLDLa
54.7 (46.2–63.2)
49.4 (43.0–55.8)
0.021
48.6 (41.7–56.5)
0.09
54.5 (45.9–63.1)
54.8 (46.2–63.4)
0.88
55.2 (45.6–64.7)
0.57
anti-PC, IgMa
778 (706–849)
812 (729–896)
0.39
822 (743–900)
0.057
797 (676–918)
742 (620–864)
<0.001
731 (596–870)
0.003
anti-PC, IgGa
861 (761–962)
879 (785–974)
0.28
859 (760–957)
0.92
913 (814–1012)
900 (802–999)
0.46
880 (764–996)
0.47
anti-PC, IgAa
837 (588–1087)
938 (640–1234)
0.027
854 (595–1112)
0.26 0.62
798 (567–1030)
772 (539–1005)
0.17
745 (357–1028)
0.42

aMean values (confidence interval 95%). bMedian values (25th to 75th percentile). P values are differences between baseline and 3 and 12 months, respectively, for each diet group. Anti-PC, antibody against phosphorylcholine; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; HAQ, Health Assessment Questionnaire; HDL, high-density lipoprotein; LDL, low-density lipoprotein; oxLDL, oxidized low-density lipoprotein.

Elkan et al. Arthritis Research & Therapy 2008 10:R34   doi:10.1186/ar2388

Open Data